Nightingale strengthens its research offering through strategic partnership

Translation: Original published in Finnish on 11/5/2025 at 3:47 pm EET.

Nightingale Health announced on Wednesday a strategic partnership with Alamar Biosciences. Through this partnership, Nightingale will integrate Alamar's brain health proteomics technology into its multiomics offering. This new service is aimed at customers in medical research. This collaboration will enable Nightingale to provide its customers with a broader range of biomarker analyses from a single blood sample. In our view, this partnership will support the company's efforts to realize the potential of the research segment in the short term while, at the same time, the ramp-up of international healthcare partnerships with greater long-term potential will require time. This news supports our estimates but does not prompt any immediate pressure to change them.

Research services expand into brain health

The partnership combines Nightingale's metabolomics analytics (i.e., the simultaneous measurement of multiple metabolites from the same sample) with Alamari's NULISA™ proteomics platform, which measures over 100 brain-related proteins from the same sample. According to the press release, the expanded service will provide researchers with new tools, particularly for researching neurodegenerative diseases, such as Alzheimer's and Parkinson's. The service is now available worldwide for medical research.

Logical step in the company's multiomics strategy

We believe the announcement is a logical continuation of Nightingale's strategy to develop a comprehensive multiomics offering for research customers. Multiomics refers to the combination of several technologies, each of which can be used to detect the concentrations of various biomarkers (e.g., proteins, metabolites, RNA, etc.) in a sample. We have previously stated that the company's research segment is its primary growth driver for the coming years, and these new services will strengthen its position in the market. The partnership announced today is a concrete example of this strategy. In our view, expanding the offering is an important way to strengthen competitiveness and support the growth of the research business, which gives the company more time to build long-term growth from healthcare partnerships.

Strategic outlook strengthened, but no need to change estimates

This news confirms our view of Nightingale's strategy and the role of its research segment as a driver of short-term growth. However, the core of the company's long-term investment story remains the large-scale commercial breakthrough of its technology for routine healthcare use, an area where this news has no direct impact. While the new service may open new research projects, its economic impact will likely be moderate and spread over a longer period. Therefore, this news does not cause any pressure to change our forecasts.